• 医学文献
  • 知识库
  • 评价分析
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
  • 临床诊疗知识库
  • 中医药知识库
  • 机构
  • 作者
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

医学文献 >>
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
热搜词:
换一批

贝伐珠单抗联合紫杉类药物治疗晚期人表皮生长因子受体2阴性乳腺癌患者的效果观察

Efficacy of bevacizumab combined with taxane drug in treating advanced human epidermal growth factor receptor-2 negative breast cancer

摘要:

目的:探讨贝伐珠单抗联合紫杉类药物治疗晚期人表皮生长因子受体2(human epidermal growth factor receptor-2,HER-2)阴性乳腺癌患者的效果。方法:以2021年1月至2023年6月于四川绵阳四〇四医院收治的61例晚期HER-2阴性乳腺癌患者为研究对象,将其中给予紫杉醇(白蛋白结合型)治疗的29例患者纳入对照组,将贝伐珠单抗联合紫杉醇(白蛋白结合型)治疗的32例患者纳入观察组。对比分析两组患者临床疗效[客观缓解率(objective response rate,ORR)和疾病控制率(disease control rate,DCR)]、治疗前后肿瘤标志物水平[癌胚抗原、糖类抗原125(carbohydrate antigen-125,CA125)、糖类抗原153(carbohydrate antigen-153,CA153)]、治疗期间不良反应。呈正态分布的计量资料以 xˉ± s表示,组间比较采用 t检验;计数资料比较采用 χ2检验或秩和检验。采用Kaplan-Meier生存曲线分析患者预后情况。 结果:治疗后观察组患者较对照组ORR和DCR明显升高[53.13%(17/32)与27.59(8/29),84.38%(27/32)与62.07%(18/29)],差异均有统计学意义( χ2值分别为4.10、3.91,均 P<0.05);观察组患者治疗后血清癌胚抗原、CA125、CA153较对照组明显降低[癌胚抗原:(15.76 ±1.89)ng/mL与(20.24 ±2.36)ng/mL,CA125:(25.78 ±3.44)kU/L与(34.66 ±4.01)kU/L,CA153:(18.34±2.19)kU/L与(24.19±3.28)kU/L],两组比较差异均有统计学意义( t值分别为8.22、9.31、8.26,均 P<0.01);两组患者治疗期间不良反应发生率比较差异无统计学意义( P>0.05);治疗后观察组患者中位疾病无进展期(progression-free survival,PFS)明显长于对照组[8个月与5个月],两组比较差异有统计学意义( χ2=7.14, P=0.008)。 结论:贝伐珠单抗联合紫衫类治疗晚期HER-2阴性乳腺癌患者近期疗效确切,可抑制肿瘤标志物表达,延长PFS,具有良好的安全性,值得临床推广应用。

更多
abstracts:

Objective:To investigate the effect of bevacizumab combined with taxanes in the treatment of advanced human epidermal growth factor receptor-2 (HER-2) negative breast cancer.Method:A total of 61 patients with advanced HER-2 negative breast cancer admitted to SiChuan Mianyang 404 Hospital from January 2021 to June 2023 were selected as the research objects, giving one to paclitaxel (albumin combined type) treatment of 29 patients in control group, will be cut bead single combined therapy with paclitaxel (albumin combined type) of 32 patients into the observation group. The clinical efficacy (objective response rate (ORR) and disease control rate (DCR)), the levels of tumor markers (carcinoembryonic antigen (CEA) and carbohydrate antigen 125 (carbohydrate)) before and after treatment were compared between the two groups CA125, carbohydrate antigen 153 (CA153), adverse reactions during treatment; Measurement data with normal distribution were represented as indicated, and comparison between groups was analyzed using the t test. Rate between group compared with chi-square test. The rank sum test was used to compare the constituent ratio of ordinal data between groups. Kaplan-Meier survival curve was used to analyze the prognosis of patients. Results After treatment, the ORR and DCR of the observation group were significantly higher than those of the control group (53.13%(17/32) vs 27.59 (8/29), 84.38% (27/32) vs 62.07% (18/29)), the differences were statistically significant ( χ2=4.10, 3.91, all P<0.05). After treatment, the serum CEA, CA125 and CA153 in the observation group were significantly lower than those in the control group (CEA: (15.76±1.89) ng/mL vs. (20.24±2.36) ng/mL, CA125: (25.78±3.44) kU/L vs (34.66±4.01) kU/L, CA125: (25.78±3.44) kU/L vs. (34.66±4.01) kU/L; CA153: (18.34±2.19) kU/L vs. (24.19±3.28) kU/L). The difference between the two groups was statistically significant ( t-values were 8.22, 9.31, and 8.26, all P<0.01). There was no significant difference in the incidence of adverse reactions between the two groups during treatment ( P>0.05). The median progression-free survival (PFS) of the observation group was significantly longer than that of the control group (8 months vs 5 months, χ2=7.14, P=0.008). Conclusions:Bevacizumab combined with taxanes in the treatment of patients with advanced HER-2 negative breast cancer has definite short-term efficacy, can inhibit the expression of tumor markers, prolong PFS, has good safety, and is worthy of clinical application.

More
作者: 赵燕 [1] 朱玥 [1] 王秀 [1] 刘君 [1]
期刊: 《中国综合临床》2024年40卷4期 291-297页 ISTIC
栏目名称: 论著
DOI: 10.3760/cma.j.cn101721-20240402-00103
发布时间: 2024-09-17
基金项目:
四川省抗癌协会临床科研(齐鲁)项目 Clinical Research (Qilu) Project of Sichuan Anti Cancer Association
  • 浏览:0
  • 下载:0

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

扩展文献

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学网小程序
new翻译 充值 订阅 收藏 移动端

官方微信

万方医学网小程序

使用
帮助
Alternate Text
调查问卷
Baidu
map